Table III.
Equilibrium Dissociation Constants (Kd) of ABP 980, Trastuzumab (EU) and Trastuzumab (US) to FcγRIa, FcγRIIa (131H), FcγRIIb, FcγRIIIa (158 V), FcγRIIIa (158F), and FcγRIIIb
| Sample | FcγRIa (pM) | FcγRIIa (131H) (μM) | FcγRIIb (μM) | FcγRIIIa (158 V) (nM) | FcγRIIIa (158F) (nM) | FcγRIIIb (μM) |
|---|---|---|---|---|---|---|
| Trastuzumab (EU) Lot #1 | 536 | 8.36 | 31.0 | 193 | 822 | 13.8 |
| ABP 980 Lot #1 | 468 | 6.91 | 26.3 | 105 | 478 | 8.14 |
| ABP 980 Lot #2 | 405 | 5.52 | 22.0 | 91.3 | 463 | 8.29 |
| Trastuzumab (US) Lot #1 | 405 | 5.74 | 24.6 | 146 | 707 | 11.8 |
Kd (pM) is reported in the table above; Trastuzumab (EU) EU authorized trastuzumab, trastuzumab (US) FDA licensed trastuzumab